TOKYO, Jan 24 (Reuters) - Shares in Japan’s Astellas Pharma Inc. tumbled nearly 5 percent on Wednesday after the U.S. authorities said it could not yet approve a new formulation of its immunosuppressant drug for heart transplant patients.
TOKYO, Jan 24 (Reuters) - Shares in Japan’s Astellas Pharma Inc. tumbled nearly 5 percent on Wednesday after the U.S. authorities said it could not yet approve a new formulation of its immunosuppressant drug for heart transplant patients.
